Skip to main content

Biocide medical gloves

Objective

To demonstrate the medical, technical and economic viability of a protective glove used by health staff (surgeons, doctors, dentists,.nurses..) against the risk of transmission of infectious diseases (AIDS, Herpes, Hepatitis, bacteria...) during medical acts (injections, blood tests, insertion and removal catheters,...).

Objectives:

Setting to work a pilot system to demonstrate the medical, technical and economic viability of a protective glove used by health staff(surgeons, doctors, dentists, nurses) against the risk of transmission of infectious diseases (AIDS, Herpes, Hepatitis, bacteria) during medical acts (injections, blood tests, insertion and removing catheters).
Innovative dimension.

The concept of a biocide glove involves new technology for a new application. The European Award awarded it for Innovation in 1995.The new technology: the biocide glove consists of three superposed elastomer layers: two external hypoallergenic layers (internal and external) and an intermediate layer composed of a biocide emulsion. In case of percutaneous accidents ("prick" and perforation of the glove) the blood inside and outside the needle is instantaneously sterilised. The new application: no biocide glove exists on the market at the present moment. The worldwide classical medical glove market (text latex gloves and surgical gloves) produces about 50 billions gloves per year. So the world-wide market for biocide gloves can be of about yearly 2 billions ECU.

Work content:
The project will include 6 main tasks as follows: Task 1: Construction of the pilot system; Task 2: Production of biocide emulsion; Task 3: Manufacturing of gloves; Task 4: Testing of biocide efficiency; Task 5: Monitoring; Task 6: Management of the project.

The minimum pilot capacity will be at least 1000 pairs of gloves per day to verify, on a scale of operations representing reality, the different aspects which might affect the implementation of the new technology. Some of the gloves produced will be used for perfecting manufacturing procedure. The remainder will be distributed to some Public Health Organisations and Medical User Glove Organisation in order to evaluate the acceptance degree of the new technology.

Expected results: A glove reducing by a factor more than 100 the risk of contamination of health staff- Manufacturing process with no defects- Manufacturing cost on an industrial scale comparable to the classical medical gloves. By the execution of this demonstration project it would be possible, with minimal risk, to build the first production line for biocide medical gloves in the European Community.

Funding Scheme

CSC - Cost-sharing contracts

Coordinator

Hutchinson SA
Address
2,Rue Balzac
75008 Paris
France

Participants (10)

Assistance Publique - Hôpitaux de Paris
France
Address
1,Place Du Parvis. Notre Dame
75181 Paris
BIOMATECH S.A.
France
Address
Rue Pasteur 115, Z.i. L'islon
38670 Chasse Sur Rhone
Hospital General Universitario Gregorio Marañon
Spain
Address
46,Calle Dr. Esguerdo
28028 Madrid
Hyghiene Institut Hamburg
Germany
Address
129A,marckmannstrasse
20539 Hamburg
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France
Address
Cours Albert Thomas 151 Adr 5 - Rhône-alpes, Auve
69424 Lyon
Institut National de la Recherche Agronomique
France
Address
7,Avenue Du Général De Gaulle
94707 Maison-alfort
Institut National de la Santé et de la Recherche Médicale
France
Address
163,Avenue De Luminy
13273 Marseille
MAPA s.n.c.
France
Address
61,Rue Marius Aufan
92305 Levallois Perret
Th. Goldschmidt AG
Germany
Address
100,Goldschmidtstrasse
45127 Essen
Universität Gesamthochschule Essen
Germany
Address
2-5,Universitatsstrasse
45141 Essen